tesaglitazar has been researched along with selegiline in 3 studies
| Studies (tesaglitazar) | Trials (tesaglitazar) | Recent Studies (post-2010) (tesaglitazar) | Studies (selegiline) | Trials (selegiline) | Recent Studies (post-2010) (selegiline) |
|---|---|---|---|---|---|
| 74 | 13 | 25 | 2,575 | 319 | 394 |
| Protein | Taxonomy | tesaglitazar (IC50) | selegiline (IC50) |
|---|---|---|---|
| Cholinesterase | Homo sapiens (human) | 0.0055 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.0039 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 1.798 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.376 | |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 0.2127 | |
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | 0.9046 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 1.4408 | |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | 0.0067 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.1001 | |
| Type-1 angiotensin II receptor | Sus scrofa (pig) | 0.048 | |
| Alpha-synuclein | Homo sapiens (human) | 0.27 | |
| Amine oxidase [flavin-containing] B | Bos taurus (cattle) | 1 | |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | 0.017 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
3 other study(ies) available for tesaglitazar and selegiline
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |